Davis Polk advised Credit Suisse Securities (USA) LLC as sole underwriter in connection with an SEC-registered offering by Corcept Therapeutics of 11,000,000 shares of its common stock for approximately $46.4 million.
Headquartered in Menlo Park, California, Corcept Therapeutics is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders.
The Davis Polk corporate team included partner Sarah K. Solum and associates Beth Hooton Ruiz, Zhimin Lin and Emily Roberts and law clerk Jahnavi Pendharkar. The tax team included partner Rachel D. Kleinberg and law clerk Catherine Paskoff Chang. Associates Emma Maconick and Daniel Ray provided intellectual property advice. All members of the Davis Polk team are based in the Menlo Park and New York offices.
Related Posts:
- Davis Polk – Altera Corporation $1 Billion Notes Offering
- Davis Polk – Vishay Intertechnology, Inc. $150 Million Convertible Senior Debentures Offering
- Davis Polk Advises E*TRADE on Common Stock Offering
- Davis Polk – BMC Software Goes Private
- Davis Polk – Altera Corporation $500 Million Notes Offering
